Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 23 min ago
Peer-reviewedCC BYChemistry & biodiversity

Therapeutic Potential of Propolis in Ulcerative Colitis: A Review of Preclinical Evidence.

  • Thayná Fernandes Barros1,2
  • Gabriel Gomes Vila Nova1,2
  • Rosane Nassar Meireles Guerra1,2
  • Flavia Raquel Fernandes do Nascimento1,2
  • Afonso Gomes Abreu1,2
  1. 1Programa De Pós-graduação em Ciências da Saúde, Universidade Federal do Maranhão, São Luís, Brazil.
  2. 2Laboratório De Imunofisiologia, Universidade Federal do Maranhão, São Luís, MA, Brazil.
Read full textPDFDOICite

Abstract

Propolis is a resinous, aromatic substance collected by worker bees from various plant species. Evidence suggests that propolis is a promising candidate for the treatment of ulcerative colitis due to its antioxidant properties and ability to modulate immune responses and the gut microbiota. This review aimed to analyze studies on the efficacy of propolis and its main active compounds in ulcerative colitis, highlighting mechanisms of action, safety and limitations. A literature search was conducted in the PubMed Central, ScienceDirect, and Scopus databases using the keywords "propolis" AND "colitis". Original articles presenting in vivo analyses, published in English up to June 2025, were included. Propolis extracts improved clinical and histopathological parameters, particularly by reducing pro-inflammatory cytokine expression, inflammatory cell infiltration, and restoring epithelial barrier integrity. These effects mainly involve modulation of inflammatory signaling pathways, particularly suppression of NF-κB activation, resulting in reduced expression of inflammatory mediators, including TNF-α, IL-1β, and iNOS. Propolis also reduced TLR4 expression, potentially contributing to the control of the exacerbated immune response characteristic of ulcerative colitis. These findings support the potential of propolis as an adjuvant agent in disease management; however, its clinical efficacy in humans remains to be validated in well-controlled and standardized studies.

Related

  1. Pharmacological and Therapeutic Potential of Garlic ( Allium sativum ): Integrating Phytochemistry, Molecular Mechanisms, and Clinical and Preclinical Evidence
    Gudisa Bereda
    ChemistryOpenPeer-reviewedCC BY 4.0Full textPlant biologyCrossrefPMC
  2. Propolis Flavonoids: Current Evidence in Animal Models and Future Promise for the Treatment of Ulcerative Colitis
    Karla Mariela Hernández-Sánchez, Oscar Nieto-Yañez, Claudia Rebeca Rivera-Yañez +8
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textZoology & animal behaviourCrossrefEurope PMC
  3. The Therapeutic Potential of Berry-Derived and Berry-Based Interventions in Inflammatory Bowel Disease: A Comprehensive Systematic Review of Preclinical and Clinical Evidence
    Lucia Carmela Passacatini, Rosamaria Caminiti, Valeria Mazza +14
    NutrientsPeer-reviewedCC BYFull textGenetics & genomicsEurope PMCCrossref
  4. Editorial: Potential therapeutic targets in alcohol use disorder: insights from recent preclinical studies
    Ilaria Morella, Priscila Vázquez-León, Valentina Vengeliene +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textNeuroscienceCrossref
  5. Therapeutic potential of oncolytic viruses in hematopoietic malignancies: from preclinical insights to clinical realities
    Sebastian Erkens, Dawit Belai Ghebrehiwot, Julius Knierer +3
    Frontiers in microbiologyPeer-reviewedCC BYFull textMicrobiologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{barros2026therapeutic,
  title = {{Therapeutic Potential of Propolis in Ulcerative Colitis: A Review of Preclinical Evidence.}},
  author = {Thayná Fernandes Barros and Gabriel Gomes Vila Nova and Rosane Nassar Meireles Guerra and Flavia Raquel Fernandes do Nascimento and Afonso Gomes Abreu},
  journal = {Chemistry \& biodiversity},
  year = {2026},
  month = oct,
  doi = {10.1002/cbdv.71886},
  url = {https://europepmc.org/article/MED/42960693},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Therapeutic Potential of Propolis in Ulcerative Colitis: A Review of Preclinical Evidence.
AU  - Thayná Fernandes Barros
AU  - Gabriel Gomes Vila Nova
AU  - Rosane Nassar Meireles Guerra
AU  - Flavia Raquel Fernandes do Nascimento
AU  - Afonso Gomes Abreu
PY  - 2026
DA  - 2026/10/30
JO  - Chemistry & biodiversity
DO  - 10.1002/cbdv.71886
UR  - https://europepmc.org/article/MED/42960693
AB  - Propolis is a resinous, aromatic substance collected by worker bees from various plant species. Evidence suggests that propolis is a promising candidate for the treatment of ulcerative colitis due to its antioxidant properties and ability to modulate immune responses and the gut microbiota. This review aimed to analyze studies on the efficacy of propolis and its main active compounds in ulcerative colitis, highlighting mechanisms of action, safety and limitations. A literature search was conducted in the PubMed Central, ScienceDirect, and Scopus databases using the keywords "propolis" AND "colitis". Original articles presenting in vivo analyses, published in English up to June 2025, were included. Propolis extracts improved clinical and histopathological parameters, particularly by reducing pro-inflammatory cytokine expression, inflammatory cell infiltration, and restoring epithelial barrier integrity. These effects mainly involve modulation of inflammatory signaling pathways, particularly suppression of NF-κB activation, resulting in reduced expression of inflammatory mediators, including TNF-α, IL-1β, and iNOS. Propolis also reduced TLR4 expression, potentially contributing to the control of the exacerbated immune response characteristic of ulcerative colitis. These findings support the potential of propolis as an adjuvant agent in disease management; however, its clinical efficacy in humans remains to be validated in well-controlled and standardized studies.
SN  - 1612-1872
SN  - 1612-1880
ER  -